Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome


An Open Label, Prospective, Stratified, Randomized, Controlled, Multi-Center, Phase IIB Study of the Impact of Thymoglobulin Therapy on Transfusion Needs of Patients With Early Myelodysplastic Syndrome (MDS)


Immunosuppressive therapy may improve bone marrow abnormalities and may be effective treatment for myelodysplastic syndrome. It is not yet known whether immunosuppressive therapy is more effective than supportive care in treating myelodysplastic syndrome.


Randomized phase II trial to compare the effectiveness of antithymocyte globulin with that of supportive care in treating patients who have myelodysplastic syndrome.

Study Status: Active, not recruiting


Condition Intervention Phase
Myelodysplastic Syndromes Biological: anti-thymocyte globulin Phase 2

Verified by Sangstat Medical Corporation March, 2003

Sponsored by: Sangstat Medical Corporation
Information provided by: National Cancer Institute (NCI) identifier: NCT00017550

Study Type: Interventional

Study Design: Allocation: Randomized, Control: Active Control, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Elizabeth C. Squiers, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site